For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for CF Industries Holdings Inc (CF) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-07): Designation Watch · Gem Score +25 (−100…+100 Quality+Value blend) · Quality 51 · Value 7 · Sentiment 40 (timing only, not weighted)
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
CF Industries Holdings Inc
CF NYSECF Industries Holdings, Inc. is a North American manufacturer and distributor of nitrogen-based products used primarily in agriculture and industrial applications. The company focuses on ammonia, granular urea, urea ammonium nitrate, ammonium nitrate, nitric acid, diesel exhaust fluid, and related nitrogen products, supplying farmers, cooperatives, distributors, and industrial customers. Its operations span production, storage, transportation, and distribution, giving it a central role in the nitrogen fertilizer supply chain. CF Industries serves both crop nutrition needs and selected industrial uses, including emissions control and other downstream chemical applications. Headquartered in Northbrook, Illinois, CF Industries is recognized as a major participant in the global market for nitrogen fertilizers and hydrogen-derived products.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics TTM · through Jun 30, 2026
EPS (Diluted): 15.97
Total Equity: $8.92B
Shares: 156,533,333
Total Debt: $3.22B
Cash: $2.48B
EBITDA: $4.07B
Total Debt: $3.22B
Cash: $2.48B
Revenue: $7.74B
Revenue: $7.74B
Revenue: $7.74B
Total Equity: $8.92B
Tax Rate: 19.5%
Equity: $8.92B
Total Debt: $3.22B
Cash: $2.48B
Current Liabilities: $772.00M
Long-Term Debt: $3.22B
Total Debt: $3.22B
Total Equity: $8.92B
Shares: 156,533,333
Shares: 156,533,333
CapEx: -$1.07B
Shares: 156,533,333
Stock Price: $133.83
Net Income: $2.50B
Industry Benchmarks
Income Statement (Annual)
Last updated: Sep 11, 2026 10:53am (26d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $6.5B | $11.2B | $6.6B | $5.9B | $7.1B |
| Cost of Revenue | $4.2B | $5.3B | $4.1B | $3.9B | $4.4B |
| Gross Profit | $2.4B | $5.9B | $2.5B | $2.1B | $2.7B |
| Operating Expenses | $658.0M | $464.0M | $315.0M | $310.0M | $424.0M |
| Operating Income | $1.7B | $5.4B | $2.2B | $1.7B | $2.3B |
| Net Income | $1.3B | $3.9B | $1.8B | $1.5B | $1.8B |
| EBITDA | $2.6B | $6.2B | $3.1B | $2.7B | $3.2B |
| EPS | $8.33 | $16.45 | $7.89 | $6.75 | $8.98 |
| EPS (Diluted) | $8.28 | $16.38 | $7.87 | $6.74 | $8.97 |
Balance Sheet (Annual)
Last updated: Sep 11, 2026 10:53am (26d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.6B | $2.3B | $2.0B | $1.6B | $2.0B |
| Total Current Assets | $2.6B | $3.7B | $3.1B | $2.5B | $3.0B |
| Total Assets | $12.4B | $13.3B | $14.4B | $13.5B | $14.1B |
| Current Liabilities | $1.4B | $995.0M | $800.0M | $818.0M | $887.0M |
| Long-Term Debt | $3.5B | $3.0B | $3.0B | $3.0B | $3.2B |
| Total Liabilities | $6.3B | $5.5B | $6.0B | $5.9B | $6.3B |
| Total Equity | $6.0B | $7.9B | $8.4B | $7.6B | $7.8B |
| Retained Earnings | $2.1B | $3.9B | $4.5B | $4.0B | $3.9B |
Cash Flow (Annual)
Last updated: Sep 11, 2026 10:53am (26d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.9B | $3.9B | $2.8B | $2.3B | $2.8B |
| Capital Expenditure | -$514.0M | -$453.0M | -$499.0M | -$518.0M | -$950.0M |
| Free Cash Flow | $2.4B | $3.4B | $2.3B | $1.8B | $1.8B |
| Acquisitions (net) | $0 | $0 | -$1.2B | $2.0M | $0 |
| Net Debt Issued / (Repaid) | -$518.0M | -$507.0M | $0 | $0 | $999.0M |
| Dividends Paid | -$260.0M | -$306.0M | -$311.0M | -$364.0M | -$326.0M |
| Stock Buybacks | -$539.0M | -$1.3B | -$580.0M | -$1.5B | -$1.4B |
| Net Change in Cash | $945.0M | $695.0M | -$291.0M | -$418.0M | $368.0M |
Growth Trends (YoY %)
Last updated: Sep 11, 2026 10:53am (26d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +71.1% | -40.7% | -10.5% | +19.3% |
| Gross Profit Growth | +145.5% | -56.6% | -19.2% | +32.5% |
| Operating Income Growth | +212.1% | -58.7% | -21.7% | +31.7% |
| Net Income Growth | +212.5% | -53.3% | -19.6% | +21.7% |
| EBITDA Growth | +138.7% | -50.4% | -13.8% | +19.7% |
Dividend History (Last 20)
Last updated: Sep 17, 2026 4:28pm (20d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-08-14 | $0.60 | — | — | — |
| 2026-05-15 | $0.50 | — | — | — |
| 2026-02-13 | $0.50 | — | — | — |
| 2025-11-14 | $0.50 | — | — | — |
| 2025-08-15 | $0.50 | — | — | — |
| 2025-05-15 | $0.50 | — | — | — |
| 2025-02-14 | $0.50 | — | — | — |
| 2024-11-15 | $0.50 | — | — | — |
| 2024-08-15 | $0.50 | — | — | — |
| 2024-05-14 | $0.50 | — | — | — |
| 2024-02-14 | $0.50 | — | — | — |
| 2023-11-14 | $0.40 | — | — | — |
| 2023-08-14 | $0.40 | — | — | — |
| 2023-05-12 | $0.40 | — | — | — |
| 2023-02-14 | $0.40 | — | — | — |
| 2022-11-14 | $0.40 | — | — | — |
| 2022-08-12 | $0.40 | — | — | — |
| 2022-05-13 | $0.40 | — | — | — |
| 2022-02-14 | $0.30 | — | — | — |
| 2021-11-12 | $0.30 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Not computed yetNarrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-09-17 16:38The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Independent read first: the TTM numbers here are running hot, not mid-cycle. Sum the four quarters through 2026-06-30 and you get roughly $7.74B revenue and $2.50B net income — a 32% net margin, up sharply from FY2024's $5.94B/$1.48B (25%) and closing on the 2022 supercycle print of $11.19B/$3.94B (35%). Sequential quarterly revenue has climbed every quarter from $1.37B (2024-Q3) to $2.22B (2026-Q2), with net income more than doubling from $341M to $869M. That is a nitrogen price spike, not secular growth. Henry Hub gas remains cheap, urea/UAN pricing is elevated on Russia/Middle East supply disruption, and CF is minting cash. At $133.83 the stock trades ~8x TTM earnings and ~5.5x EV/EBITDA — cheap on the print, but the print is a peak.
The synthesis verdict of "$422 fair value, +331%" is nonsense and should be discarded. It's a DCF that extrapolates peak-cycle FCF as steady-state; no serious nitrogen analyst underwrites CF at 3x current price. The pre-flight and market-forces layers have this right — this is a commodity cyclical whose earnings power ranges from ~$1.26B (2021) to $3.94B (2022) to $1.48B (2024) to ~$2.5B TTM. Normalize over the 2021-2025 window and you get ~$2.06B average net income, or roughly $14/share on 149M shares. At a fair 10-12x mid-cycle multiple that's $140-170 — meaning the stock is actually trading near fair mid-cycle value, not at a 76% discount. The 37% "earnings CAGR" and 20% "revenue YoY" are cycle artifacts, not a trend line.
The contrarian bull case is narrower than the DCF suggests but real: (1) Green/blue ammonia optionality (Donaldsonville CCS, JERA/Mitsui JV) offers a genuine call option on decarbonization demand that isn't in TTM numbers; (2) US gas cost advantage vs European TTF-linked producers is structural — European ammonia capacity keeps getting mothballed; (3) $1.98B cash against $3.22B debt and $1.80B FCF supports aggressive buybacks (share count has fallen ~35% over five years). The bear case: nitrogen prices mean-revert hard when Russian/Belarusian supply normalizes or when corn acreage disappoints, and the insider activity is 100% A-Awards with zero open-market buying — management is taking stock, not paying for it. That's neutral-to-slightly-negative, not the "Neutral" the secondary signal claims when you consider they have peak-cycle information advantage.
Where the models diverge usefully: market-forces (Neutral, mean-reversion risk) and the narrative layer (cyclical-late-stage, anchored, moderate durability) are internally consistent and correct. The valuation synthesis is broken because it's applying growth-company DCF logic to a commodity cyclical at peak margins — this is exactly the regime-inappropriate misuse the brief warns about. The rule-based "mature earner" label undersells the cyclicality. My read: at 8x peak earnings CF is neither the screaming buy the DCF claims nor obviously overvalued; it's roughly fair for someone comfortable with cycle risk, with the catalyst being either (a) nitrogen prices staying elevated into 2027 crop cycle or (b) clean ammonia contracts monetizing. I'd dissent from "undervalued +331%" and land at fairly valued with a slight lean to overvalued if you believe mean reversion begins in 2026-H2. A reasonable entry is closer to $105-115 (giving you ~7x mid-cycle earnings with a cyclical margin of safety); at $134 you're paying full mid-cycle price for a stock that will earn less next year than this year with meaningful probability.
GPT Reading
What stands out is not “cheap fertilizer stock,” but a business in the favorable part of its cycle with numbers that are strong enough to justify a premium to its own history, though not the absurd DCF-style upside suggested by the model. On the trailing twelve months through 2026-06-30, CF generated about $7.74B of revenue and $2.50B of net income, versus $6.44B and $1.58B in the prior TTM, so growth is running roughly 20% on sales and 58% on earnings. That acceleration is visible quarter by quarter: revenue climbed from $1.37B in 2024-09 to $2.22B in 2026-06, while net margin expanded from 24.9% to 39.1%. A commodity producer posting 42.5% gross margin, 41.1% operating margin, and 32.3% net margin is not merely surviving a cycle; it is harvesting a structural advantage. The balance sheet supports that interpretation: debt is only $3.22B against $1.98B of cash, current ratio is 4.86, and annual free cash flow was already $1.80B at 2025 year-end before the stronger 2026 run-rate showed up. At $133.83, the stock trades at 8.4x TTM earnings and 5.5x EV/EBITDA, which is not expensive for a company producing near-30% ROE and 26.5% ROIC.
The key issue is whether those returns are fleeting. I think the market is still applying a substantial cyclical discount, but reasonably so. CF is not a compounder in the usual sense; 2022 revenue of $11.19B and net income of $3.94B prove how violent the fertilizer cycle can get, while 2024 dropped back to $5.94B and $1.48B. Even so, today’s earnings power looks better than a simple “reversion to normal” bear case suggests. The TTM revenue base of $7.74B is already above 2025’s $7.08B and well above 2024’s $5.94B, while quarterly profits have improved in four straight reported quarters from $460M to $869M. That kind of progression implies not just a dead-cat rebound in pricing but a business whose cost position lets incremental price strength flow through disproportionately. For a U.S. nitrogen producer, cheap domestic gas relative to global peers is a real edge, and the income statement is showing it. I would not pay a market multiple for those earnings, but I also would not normalize CF all the way back to 2024 profitability when the current run-rate is materially higher and the company remains financially disciplined.
The strongest case against this view is that the stock may already reflect a generous mid-cycle earnings assumption even if the P/E looks low. Using the current market cap of $19.98B against TTM net income of roughly $2.50B gives the 8x multiple, but if earnings slide back toward 2024’s $1.48B or even 2025’s $1.80B, that multiple quickly becomes 11-14x on a more normalized base. For a no-growth, capital-intensive commodity producer, that is not obviously cheap, especially with capex at $950M and dividend yield only 1.6%. The annual history also warns against extrapolation: 2023 revenue was $6.63B, then 2024 fell to $5.94B before recovering, so there is nothing linear here. If fertilizer prices weaken or global supply normalizes, the 39.1% latest-quarter net margin can compress fast. On that reading, the valuation-synthesis output calling for $422 or even $577 fair value is not just aggressive; it is detached from the economics of a cyclical producer whose best year, 2022, was clearly abnormal. I reject that upside entirely.
Still, I weigh the current setup more favorably than the bears because valuation already bakes in a lot of skepticism while the actual operating trend is improving, not deteriorating. A $19.98B market cap against an annualized earnings run-rate north of $2.5B and FCF capability likely above the 2025 level gives the company room to keep returning capital even if margins soften. The low payout ratio of 12.6% means the dividend is not stressed, and the modest net debt means CF does not need heroic conditions to remain highly profitable. What would change my mind is simple: if the next couple of quarters show revenue stalling back toward the $1.6B-$1.8B range and net margins falling into the low-20s, I would conclude 2026 was just another temporary upswing and fair value is closer to $105-$115. Conversely, if CF can sustain quarterly revenue around $2.0B+ with net income above $600M while keeping capex contained and cash generation strong, then the stock deserves to hold or exceed today’s level and could justify something in the $150-$165 range without relying on peak-cycle fantasy.
Grok Reading
The raw numbers on CF Industries describe a low-cost nitrogen producer whose earnings power has re-accelerated hard after the 2023–24 trough. Trailing twelve-month revenue through mid-2026 runs roughly $7.74B (2.22 + 1.99 + 1.87 + 1.66), with net income of about $2.50B and a 32% net margin—well above the $1.80B earned on $7.08B in calendar 2025 and dramatically better than the $1.48B on $5.94B in 2024. Sequential margin expansion is unmistakable: net margin climbed from 21–26% through most of 2025 into 34% and then 39.1% in the two most recent quarters. Returns are elite for a basic-materials name—TTM ROE near 30%, ROIC 26.5%, operating margin 41%—while the balance sheet is fortress-like (net debt only ~$1.2B against $1.98B cash, D/E 0.36, current ratio 4.9). Free cash flow of $1.80B in 2025 on only $950M of capex, paired with a 12.6% payout and 1.6% dividend yield, leaves substantial capacity for buybacks. At $133.83 the stock screens cheap on every conventional multiple: 8.4× TTM earnings, 5.5× EV/EBITDA, 2.7× sales. The story the data tell is of a cost-advantaged U.S. gas-based producer capturing elevated global nitrogen pricing and converting it into outsized cash generation.
That said, the quantitative models’ claim of a $422–$577 fair value (implying +330% upside) is disconnected from the same underlying data and should be discarded. Those figures effectively capitalize near-peak or still-elevated margins in perpetuity for a classic mature-earner commodity cycle company whose 2022 supernormal year produced $11.2B of revenue and $3.94B of net income—levels not yet re-attained. Current TTM results sit between the mid-cycle trough and that peak; treating 32–39% net margins as the terminal state produces a fantasy DCF. Market Forces correctly flags the mean-reversion risk that the Valuation Synthesis ignores. CF remains a pure-play on nitrogen prices and the spread between U.S. natural gas and higher-cost global production. Revenue CAGR of ~15% and earnings CAGR of 37% look impressive only because they are measured off a depressed base; they are not structural growth rates. The 2.35× book multiple and mid-single-digit EV/EBITDA already embed a decent amount of the cost-advantage narrative without requiring hero assumptions.
The strongest case against an undervalued read is precisely that cyclically adjusted earnings power is lower than trailing results imply. If nitrogen pricing normalizes and net margins settle in the low-to-mid 20s—consistent with 2023–25 rather than the latest two quarters—TTM net income could drift back toward $1.6–1.9B. At a still-reasonable 11–13× multiple that supports a mid-teens to low-$20s billion equity value, i.e., only modest upside or even flat from today’s $20B market cap. Macro headwinds in agriculture, potential new capacity, and any narrowing of the U.S. gas advantage would accelerate that compression. Insider activity is pure awards, offering no confirmatory buy signal, and the modest dividend leaves the equity story almost entirely dependent on the commodity tape and capital-return execution. A smart opponent would also note that 8× earnings on peakish margins is not the same as 8× mid-cycle earnings; the multiple looks cheap only while the numerator stays inflated.
I still land modestly bullish because the current run-rate cash generation, pristine balance sheet, and structural cost position give the company more earnings durability than a generic fertilizer name, and the market is not awarding any scarcity premium. The stock does not need 2022 conditions to justify a higher price; it merely needs margins to avoid collapsing back to the trough. What would flip the verdict is clear: two consecutive quarters of revenue back below $1.7B and net margins compressing through 25% would signal the cycle has rolled and turn the 8× multiple into a value trap. Conversely, sustained nitrogen strength that keeps TTM net income above $2.3B while FCF continues to fund aggressive buybacks would justify re-rating toward 11–12× and push the shares well above $160. Until one of those paths clarifies, the data support a discounted but not deeply distressed cyclical.
Qwen Reading local experiment · off-panel
The most glaring contradiction in this briefing is the Valuation Synthesis model’s output, which claims a composite fair value of $422.16 and a signal-adjusted value of $577.16 against a current price of $133.83. This is a mathematical absurdity that reveals a fundamental failure in the model’s input assumptions. The model is likely extrapolating the trailing twelve-month (TTM) net income of approximately $2.5 billion (derived from the recent quarterly surge: $869M + $676M + $495M + $460M) as a permanent, normalized run-rate. However, CF Industries is a pure-play commodity producer whose earnings are inextricably linked to the spread between nitrogen fertilizer prices and natural gas costs. The 2022 peak saw revenue of $11.19B and net income of $3.94B, but the 2025 annual net income was $1.80B, and the 2024 figure was $1.48B. The recent quarterly explosion in margins (39.1% in Q2 2026 vs. 26% in Q2 2025) is a cyclical spike, not a structural shift. To value CF at $577, you would need to assume that the company can sustain ~$2.5B in annual net income indefinitely while growing at a double-digit CAGR, which is physically impossible for a commodity business with no pricing power over its end product. The market is not "wrong" here; the model is.
The underlying data tells a story of a company in the late stage of a commodity upcycle, not a growth engine. The "Momentum" section cites a 37.3% earnings CAGR and 58.6% recent YoY earnings growth, but this is a classic cyclical trap. The 2021-2023 period was an anomaly driven by the Russia-Ukraine war and energy shocks. The 2024 and 2025 annual figures show a normalization back toward $1.5B-$1.8B in net income. The current TTM P/E of 8.38x is not a "deep value" signal; it is a cyclical peak multiple. Historically, commodity stocks trade at low P/E multiples at the top of the cycle because earnings are at their peak, and high P/E multiples at the bottom because earnings are depressed. Buying CF at an 8.4x P/E when margins are at 39% is akin to buying a tech stock at 50x P/E when growth is slowing. The "Mature Earner" archetype classification is correct, but the valuation logic applied to it is flawed. The 2.35x P/B is reasonable for a company with 29.9% ROE, but that ROE is inflated by the current cycle.
The strongest case against my bearish read would be the "structural floor" argument: that geopolitical tensions and the high cost of entry for new nitrogen capacity (due to energy costs) have permanently raised the margin floor. The data supports that CF has a genuine cost advantage from cheap US natural gas, and the 4.86 current ratio and low debt-to-equity of 0.36 show a fortress balance sheet. The free cash flow of $1.80B in 2025 is robust. However, this is a "cash cow" story, not a "growth" story. The market is pricing in a return to normalized margins, not a permanent 39% net margin. The "Market Forces" signal correctly identifies "mean-reversion risk," but the Valuation Synthesis model ignores it entirely. The 76% discount to DCF mentioned in the narrative is a red flag for the DCF model’s reliability, as it likely uses the same flawed growth assumptions. The insider activity is neutral, with only small A-Award transactions, offering no signal of management confidence in a re-rating.
What would change my mind is a sustained shift in the global nitrogen supply-demand balance that is not driven by temporary geopolitical shocks. If CF can demonstrate that its cost advantage allows it to maintain 30%+ net margins even when global fertilizer prices normalize, that would be a structural change. However, the data shows that when prices normalized in 2024, margins dropped to 21-26%. The 2026 quarterly data shows a rebound, but this is likely due to seasonal demand and continued energy cost differentials, not a new equilibrium. The specific number to watch is the Q3 2026 net margin. If it drops below 30% while revenue remains stable, it confirms the cyclical nature of the earnings. If it holds above 35%, it suggests a structural shift. But given the commodity nature of the business, the former is far more likely. The stock is not undervalued; it is fairly valued for a cyclical peak, and the risk of mean reversion is high.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
CF is a mature commodity earner whose economics ride the nitrogen cycle: revenue peaked at $10.16B in 2022 with 52% gross and 44% operating margins, troughed at $5.89B / 33.4% GM / 27.4% OpM in 2024, and has recovered to $7.74B / 42.5% GM / 41.1% OpM in the TTM to Jun-2026 with $2.50B net income and $1.91B FCF. Cash conversion is a genuine strength: OCF/NI of 1.37x, accruals of -5.5% of assets, Beneish -2.5, and Altman Z of 3.83 all point to clean earnings and no mechanical red flags.
Verify before trusting this (5)
- Long-term debt maturity ladder and covenant headroom given $736M net debt position
- Natural gas cost structure and hedging - the durability of the North American Henry Hub cost advantage vs European producers
- Green/blue ammonia capex commitments (Donaldsonville, Blue Point JV) and whether they preserve current FCF trajectory
- Customer concentration in industrial nitrogen and any long-term offtake pricing
- Whether the 2023 share count spike (197.6M vs 151.8M in 2022) reflected an actual issuance event or accounting anomaly
The e2e composite fair value of $422 and signal-adjusted $577 are almost certainly runaway outputs - the anchored-PE bucket at $800 is anchoring on peak-cycle EPS from the 2022-2023 nitrogen supercycle and should be heavily discounted. The credible anchors are the DCF at $371 and the EPV floor at $146. EPV is the honest downside marker: if nitrogen normalizes fully, the earnings power alone justifies roughly today's price ($146 vs $134). The DCF suggests real upside if mid-cycle economics hold, but a skeptical mid-cycle deserved value probably sits in the $170-200 range, not $400+.
Verify before trusting this (5)
- Realized nitrogen prices vs 5-year average in latest 10-Q
- Blue Point ammonia project capex schedule and expected returns
- Buyback pace and remaining authorization
- Nat gas cost curve and any hedges
- Management commentary on Chinese urea export policy and EU supply
CF is not a story stock and doesn't need to be right now. The tape just went risk-off (VIX 17.7, S&P off its highs), but with a 0.4 beta and a defensive ag-inputs profile, that macro headwind lands softly here; low-beta cash generators are exactly what money rotates INTO when risk comes off. The active narrative is minimal-intensity and moderately durable, which means there's no fragile bull story to crack and no cult premium to unwind. Momentum is the dominant force: +24% over three months, +20% recent vs 14.7% long-term CAGR, and news flow is explicitly framing the rally around firm nitrogen prices, tight supply, and shareholder returns. That is a self-reinforcing tailwind. The bear framing (commodity reversion, normalized margins) is a valuation debate, not a sentiment attack - nobody is short-selling the narrative here. Net: a modest, durable tailwind from price action and constructive commodity headlines, only lightly offset by a nascent risk-off regime that this specific profile is well-insulated from.
Verify before trusting this (4)
- Nitrogen/urea spot price trajectory and any signs of Chinese export normalization loosening supply
- Whether the risk-off regime deepens beyond one day and starts pulling commodity cyclicals down with it
- Sell-side target revisions after the 24% rally - stale targets getting bumped would extend the tailwind
- Ag-sector rotation signals (corn, soy planting intentions) that could crack or reinforce the demand story
The world is doing two contradictory things to CF. Energy geopolitics — European gas cost, Russian trade friction, Chinese export discipline — keeps the global nitrogen cost curve steep and hands a North American gas producer an unearned spread; that is the tailwind and it has persisted longer than skeptics assumed. Against it, row-crop economics are poor, which caps how much of that spread growers can absorb, and rising US LNG exports slowly erode the absolute gas advantage. Macro backdrop is a headwind with a 5% 10-year, which matters mainly for the multi-year Blue Point capex cycle. Net: a supportive but not extendable environment — CF should earn well above its own historical mid-cycle for another year or two without the growth rate itself continuing to rise.
Prediction unavailable. valuation-synthesis has no result for CF — the prediction needs its fair-value anchors.